We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.05%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$630M
AUM Growth
+$66.5M
Cap. Flow
+$74.6M
Cap. Flow %
11.85%
Top 10 Hldgs %
30.71%
Holding
120
New
23
Increased
22
Reduced
38
Closed
13

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$79.9M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.1M
3
MRK icon
Merck
MRK
+$12.3M
4
AGN
Allergan plc
AGN
+$6.72M
5
BMY icon
Bristol-Myers Squibb
BMY
+$6.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20M
2
PFE icon
Pfizer
PFE
+$13.2M
3
MDT icon
Medtronic
MDT
+$11M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.02M
5
CPHD
Cepheid Inc
CPHD
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.01%
2 Financials 0.83%
3 Technology 0.09%
4 Energy 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHPG
1
DELISTED
Shire pic
SHPG
$26.6M 4.22%
+409,858
New +$79.9M
LLY icon
2
Eli Lilly
LLY
$1.02T
$20.5M 3.25%
255,000
+20,000
+9% +$1.6M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$19.8M 3.15%
161,702
-61,380
-28% -$7.9M
CELG
4
DELISTED
Celgene Corp
CELG
$19.4M 3.09%
186,000
-13,000
-7% -$1.41M
AGN
5
DELISTED
Allergan plc
AGN
$18.3M 2.91%
79,500
+27,500
+53% +$6.72M
UNH icon
6
UnitedHealth
UNH
$376B
$18.2M 2.89%
130,000
+45,000
+53% +$6.3M
BIIB icon
7
Biogen
BIIB
$30B
$17.8M 2.83%
57,000
-23,000
-29% -$6.81M
INCY icon
8
Incyte
INCY
$24.2B
$17.4M 2.77%
185,000
+15,000
+9% +$1.26M
CVS icon
9
CVS Health
CVS
$133B
$14.2M 2.26%
160,000
+40,000
+33% +$3.78M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.6B
$13M 2.06%
140,000
-10,000
-7% -$942K
BMY icon
11
Bristol-Myers Squibb
BMY
$133B
$12.8M 2.03%
237,000
+100,000
+73% +$6.42M
MRK icon
12
Merck
MRK
$322B
$12.5M 1.98%
+209,600
New +$12.3M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$40.8B
$12.4M 1.97%
+270,000
New +$14.1M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$78.5B
$11.9M 1.88%
29,500
-20,000
-40% -$8.02M
ZBH icon
15
Zimmer Biomet
ZBH
$18.2B
$11.1M 1.76%
87,550
+14,420
+20% +$1.78M
CI icon
16
Cigna
CI
$73.7B
$10.9M 1.74%
84,000
-15,000
-15% -$1.96M
ABMD
17
DELISTED
Abiomed Inc
ABMD
$10.9M 1.74%
85,000
-20,000
-19% -$2.4M
ARIA
18
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$9.24M 1.47%
675,000
+50,000
+8% +$502K
AMGN icon
19
Amgen
AMGN
$208B
$9.17M 1.46%
55,000
-6,500
-11% -$1.1M
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$27.5B
$8.81M 1.4%
130,000
-65,000
-33% -$4.59M
HCA icon
21
HCA Healthcare
HCA
$87.2B
$8.32M 1.32%
110,000
+10,000
+10% +$766K
ALKS icon
22
Alkermes
ALKS
$8.22B
$8.26M 1.31%
175,599
+40,000
+29% +$1.9M
ESRX
23
DELISTED
Express Scripts Holding Company
ESRX
$7.83M 1.24%
111,000
-5,000
-4% -$374K
EXEL icon
24
Exelixis
EXEL
$13.3B
$7.67M 1.22%
600,000
-200,000
-25% -$2.16M
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$15.9B
$7.29M 1.16%
60,000
-10,000
-14% -$1.35M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rhenman & Partners Asset Management held 120 positions worth $630M, up 12% from $563M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $74.6M of net new capital in Q3 2016, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Shire pic: 409,858 shares worth $26.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.02M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2016 buy was Shire pic: 409,858 shares worth $26.6M.
  • Rhenman & Partners Asset Management added most to Allergan plc in Q3 2016, an estimated $6.72M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2016 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.02M.
  • Rhenman & Partners Asset Management fully exited Gilead Sciences in Q3 2016, selling an estimated $20M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $630M portfolio in Q3 2016.
  • Rhenman & Partners Asset Management opened 23 new positions and closed 13 in Q3 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $630M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2016, filed 8 Nov 2016.